The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
A Universal Clinical Test For Gene Fusions In Blood Cancer
Funder
National Health and Medical Research Council
Funding Amount
$628,001.00
Summary
Mis-repair of broken chromosomes results in gene fusion and is a common feature of blood cancers. Current tests are only capable of detecting well-known gene fusions and are incapable of identifying new fusion events or fusion variations. We have developed a scientific technique, termed CaptureSeq, that can address these issues. We propose to use this technique as the foundation for a single clinical test for blood cancers, capable of detecting all possible fusion variations – known and unknown.
Diagnosing Chromosomal Translocations In Solid Tumours
Funder
National Health and Medical Research Council
Funding Amount
$410,997.00
Summary
Mis-repair of broken chromosomes can fuse together genes that then cause cancer. Current clinical tests are only capable of detecting single well-known gene fusions and are incapable of identifying new fusion events or fusion variations. We have developed a diagnostic technology, termed CaptureSeq, that is capable of finding all fusion genes in a patient sample. In this grant, we will demonstrate the use and advantages of CaptureSeq for diagnosing fusion genes in cancer patients.
A Functional Assay To Classify Genetic Variants In Lynch Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$368,195.00
Summary
At least one person in every 1000 is affected by Lynch syndrome, in which faulty DNA repair machinery causes high rates of cancer. People with Lynch syndrome can have their risk of cancer cut substantially with regular screening. However, we often struggle to understand whether people with 'non-standard' DNA sequences in particular genes actually have Lynch syndrome. This project develops a simple test that will tell clinicians whether a given sequence change relates to Lynch syndrome or not.
Liquid Biopsy For Personalised Monitoring Of Melanoma Patients
Funder
National Health and Medical Research Council
Funding Amount
$820,888.00
Summary
Despite the success of recent melanoma treatments, therapies are effective long term in only a proportion of patients. Here we will progress preliminary findings in collaboration with biotechnology and pathology companies to develop highly effective companion biomarkers that will aid treatment decisions throughout disease course. Our team will spearhead translation of these markers into the clinic for routine monitoring of melanoma patients.
Modelling Epigenomic Change During Early Breast Carcinogenesis Using In Vitro And In Vivo Model Systems
Funder
National Health and Medical Research Council
Funding Amount
$743,360.00
Summary
Epigenetics describes how genes can be turned on and off without a change in the DNA sequence. Epigenetic changes are common and often occur early in cancer, but we do not know where or how epigenetic changes occur in cancer. In this proposal we will create the first detailed map of the epigenetic landscape of normal and cancer breast cells. These maps will allow us to predict where epigenetic lesions occur in breast cancer, which will have important diagnostic and therapeutic value for cancer t ....Epigenetics describes how genes can be turned on and off without a change in the DNA sequence. Epigenetic changes are common and often occur early in cancer, but we do not know where or how epigenetic changes occur in cancer. In this proposal we will create the first detailed map of the epigenetic landscape of normal and cancer breast cells. These maps will allow us to predict where epigenetic lesions occur in breast cancer, which will have important diagnostic and therapeutic value for cancer treatments.Read moreRead less
Circulating Tumour DNA As A Personalized Biomarker In ER Positive Metastatic Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This PhD aims to study the use of liquid biopsies for disease monitoring in metastatic estrogen receptor positive breast cancer. Liquid biopsies involve looking for circulating cancer-specific genetic material in the blood stream. Through the use of liquid biopsies, we hope to understand genetic differences and heterogeneity within metastatic breast cancer; identify potential therapeutic targets; and examine the mechanisms of treatment resistance to facilitate personalised cancer therapy.